Enlivex Therapeutics Ltd. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2013 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Enlivex Therapeutics Ltd. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2013 to Q4 2023.
  • Enlivex Therapeutics Ltd. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $22.3M, a 23.1% decline year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $22.3M -$6.68M -23.1% Dec 31, 2023 20-F 2024-04-30
Q4 2022 $28.9M +$2.92M +11.2% Dec 31, 2022 20-F 2024-04-30
Q4 2021 $26M +$5.93M +29.5% Dec 31, 2021 20-F 2023-04-10
Q4 2020 $20.1M +$14.5M +258% Dec 31, 2020 20-F 2022-04-29
Q4 2019 $5.62M +$2.24M +66.1% Dec 31, 2019 20-F 2021-04-30
Q4 2018 $3.38M +$744K +28.2% Dec 31, 2018 20-F 2021-04-30
Q4 2017 $2.64M +$501K +23.4% Dec 31, 2017 20-F 2020-04-30
Q4 2016 $2.14M -$3.63M -62.9% Dec 31, 2016 20-F 2019-04-30
Q4 2015 $5.77M +$3.97M +222% Dec 31, 2015 20-F 2017-02-24
Q4 2014 $1.79M +$1.48M +474% Dec 31, 2014 20-F 2016-03-29
Q4 2013 $312K Dec 31, 2013 20-F 2015-03-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.